Tags |
|
|
Links |
|
|
Atricle Dump - Aleve, Vioxx, Celebrex, and Bextra: What You Need To Know About Arthritis Pain Medications
Rogue nation-states of the world are indeed often extremely boisterous and their rhetoric is often very negative. Once such a nation pushed too hard against the free-world there is a good chance of political impasse leading to war. In the midst of the conflict, the rogue nation will sometimes become desperate as the world closes in on them.One last ditch tactic of a nation-state defending itself might be to take out "all" communication on both sides, for instance attempt to "flash" the satellites and send a large rocket up very high with a huge electromagnetic pulse or many such rockets simultaneously. The goal here would be to remove all communication and render the smart munitions useless, wipe out Air
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding ass
Regardless of who you are: an individual, business organization, religious organization, military, proofreading and editing services are required to deal with all manner of errors we face in the course of producing our documents. In-fact, proofreading and editing services are a vital aspect of human activity as most business transactions are conducted in printed form. However, as a result of time constraint and dearth in skilled human resources, some organizations outsource part of this function to professional writers and editors.The tasks usually discharged by professional editors include: proofreading, copyediting, revision, and writing of publications. Let me briefly consider each of them.1. P
The survey also showed that now, more than ever, those with arthritis need to understand the benefits and possible side effects associated with all arthritis pain medications. In order to do so, people with arthritis, their caregivers and families must be familiar with recent news about the two types of drugs most commonly used to treat arthritis pain – non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), and another group of NSAIDs known as cyclooxygenase-2 (COX-2) specific inhibitors.
COX-2 specific inhibitors vs. Other NSAIDs
COX-2 specific inhibitors are the newest members of the NSAID class of medications. Available by prescription only, they became widely used in recent years to reduce joint pain and swelling. COX-2 specific inhibitors work by selectively blocking, or inhibiting, one of the two enzymes associated with inflammation. Some experts think that this selective inhibition may be one reason for some of the negative side effects currently associated with COX-2 specific inhibitors.
Non-selective NSAIDs were developed earlier than COX-2 specific inhibitors and have been widely used to relieve arthritis pain and inflammation for many years. Unlike COX-2 specific inhibitors, non-selective NSAIDs inhibit both major enzymes involved in the inflammatory process, COX-1 and COX-2. The non-selective NSAID category includes a number of different medications that are available in both prescription and over-the-counter (OTC) products.
Timeline of Events
To understand the current state of affairs, it is important to understand the sequence of events. The controversy started when a study published in the October 21, 2004, issue of the New England Journal of Medicine cited the COX-2 specific inhibitor, Vioxx as potentially causing “major adverse events,” including heart attack and stroke, among patients taking the drug. As a result, Merck (the drug’s manufacturer) voluntarily withdrew Vioxx from the market. However, in the months following, the safety of the other available COX-2 specific inhibitors such as Celebrex and Bextra, as well as other arthritis pain medications in the non-steroidal anti-inflammatory (NSAID) class, were also called into question.
Consequently, in February 2005, the US Food and Drug Administration (FDA) convened a special Advisory Committee, made up of members of the Arthritis and Drug Safety Advisory Committees, to review the cardiovascular safety of these arthritis pain medications.
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding asso
What are tags?Tags are a way of categorizing. They're used for blogs, pictures, social bookmarking, articles, and more. Instead of the traditional categories, tags allow you to create categories "on the fly". They're then grouped together in a tag cloud, with the most popular tags in a larger font.Using tags for the most exposure.Tags give you a lot of freedom and they're easy to use. Choosing the right tags can sometimes be a little more difficult. If somebody is looking for specific information on, say, blogging tips, they might look under the tag, "blog". But you tagged your blog, "blogging tips" and your blog won't be found.A good strategy when it comes to tagging i
COX-2 specific inhibitors vs. Other NSAIDs
COX-2 specific inhibitors are the newest members of the NSAID class of medications. Available by prescription only, they became widely used in recent years to reduce joint pain and swelling. COX-2 specific inhibitors work by selectively blocking, or inhibiting, one of the two enzymes associated with inflammation. Some experts think that this selective inhibition may be one reason for some of the negative side effects currently associated with COX-2 specific inhibitors.
Non-selective NSAIDs were developed earlier than COX-2 specific inhibitors and have been widely used to relieve arthritis pain and inflammation for many years. Unlike COX-2 specific inhibitors, non-selective NSAIDs inhibit both major enzymes involved in the inflammatory process, COX-1 and COX-2. The non-selective NSAID category includes a number of different medications that are available in both prescription and over-the-counter (OTC) products.
Timeline of Events
To understand the current state of affairs, it is important to understand the sequence of events. The controversy started when a study published in the October 21, 2004, issue of the New England Journal of Medicine cited the COX-2 specific inhibitor, Vioxx as potentially causing “major adverse events,” including heart attack and stroke, among patients taking the drug. As a result, Merck (the drug’s manufacturer) voluntarily withdrew Vioxx from the market. However, in the months following, the safety of the other available COX-2 specific inhibitors such as Celebrex and Bextra, as well as other arthritis pain medications in the non-steroidal anti-inflammatory (NSAID) class, were also called into question.
Consequently, in February 2005, the US Food and Drug Administration (FDA) convened a special Advisory Committee, made up of members of the Arthritis and Drug Safety Advisory Committees, to review the cardiovascular safety of these arthritis pain medications.
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding ass
A number of Internet sites now invite you to submit articles with the promise that you will receive payment if what you have written is popular with the users. This sounds great, but be sure to read the fine print!For example, one site says that if your material is popular with their readers, you will "share the revenue." Nowhere does it indicate how much this could or will be. That's probably because they don't have any revenue yet. If and when they do, you'll get some unknown percentage of it. Presumably, your cut will also depend on how many other writers are being rewarded at the same time for the most popular articles in their category. The upshot is: you can't know how much, if anything, you will r
Non-selective NSAIDs were developed earlier than COX-2 specific inhibitors and have been widely used to relieve arthritis pain and inflammation for many years. Unlike COX-2 specific inhibitors, non-selective NSAIDs inhibit both major enzymes involved in the inflammatory process, COX-1 and COX-2. The non-selective NSAID category includes a number of different medications that are available in both prescription and over-the-counter (OTC) products.
Timeline of Events
To understand the current state of affairs, it is important to understand the sequence of events. The controversy started when a study published in the October 21, 2004, issue of the New England Journal of Medicine cited the COX-2 specific inhibitor, Vioxx as potentially causing “major adverse events,” including heart attack and stroke, among patients taking the drug. As a result, Merck (the drug’s manufacturer) voluntarily withdrew Vioxx from the market. However, in the months following, the safety of the other available COX-2 specific inhibitors such as Celebrex and Bextra, as well as other arthritis pain medications in the non-steroidal anti-inflammatory (NSAID) class, were also called into question.
Consequently, in February 2005, the US Food and Drug Administration (FDA) convened a special Advisory Committee, made up of members of the Arthritis and Drug Safety Advisory Committees, to review the cardiovascular safety of these arthritis pain medications.
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding ass
NEWS FLASH: Government Grant scams are running rampant all over the United States. But you must understand that the government is NOT in the business of giving away free money for the sake of giving away money. Contrary to what a lot people are led to believe, "free grants" do not exist -- at least, not in the way we might believe. Like most con artists, the free-money hucksters take a grain of truth and distort it.No government group or charitable organization is going to give you money without asking themselves, "What's in it for me?" In addition, the American people would never stand for the government setting individuals up in business at no cost -- and all at taxpayer risk.A grant is a gift
Consequently, in February 2005, the US Food and Drug Administration (FDA) convened a special Advisory Committee, made up of members of the Arthritis and Drug Safety Advisory Committees, to review the cardiovascular safety of these arthritis pain medications.
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding ass
If you run a non-profit group you must be very tactful and be sure to thank everyone who helped you with your fundraising event. Including any business, individuals or organization, which allowed you to use their property. This community goodwill is extremely important because we all know that public fundraising events never go perfectly. In fact there is always something that aggravates the volunteers or property owners, who take a little bit of a risk even allowing you to do something on their property.Below is a copy of a sample Thank You Letter to a property owner for allowing a non-profit group to have a car washing fundraiser on their property. You will of course need to adjust it to fit your non-p
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
• Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
• All prescription NSAIDs must revise their labeling to include a “black box” warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding associated with these drugs. Celebrex, the only COX-2 specific inhibitor remaining on the US market, was included in this directive.
• All OTC NSAIDs (except aspirin) will be required to revise their labeling to include more specific information about the potential for GI and CV side effects, a stronger reminder to follow label instructions, as well as a warning about potential skin reactions.
To further evaluate the potential for increased CV risk, the FDA also announced that all NSAIDs must conduct and submit to the FDA a comprehensive review and analysis of pertinent safety data from clinical trials.
• Aleve (naproxen sodium) is supported by clinical studies conducted to gain approval of naproxen as a prescription product and as OTC that do not provide any evidence of increased risk of cardiovascular events.
Treatment Options: What Should Arthritis Patients Know?
For some people who suffer from pain associated with arthritis, their symptoms can be managed with exercise, heat/cold therapy, joint protection, assistive devices, weight control, or in some severe cases, surgery. For others, medications are needed to help manage the symptoms associated with arthritis.
When taken as directed OTC medications such as Aleve provide a safe and effective way to treat mild to moderate pain of minor arthritis. If patients have questions, they should consult their health care professional about which treatment option is most appropriate.
Why It’s Important to Treat Arthritis
Arthritis affects approximately 66 million Americans and is the nation’s leading cause of disability. There are over 100 different types of arthritis, and they all have different symptoms that vary in severity from person to person. The most common form of arthritis, osteoarthritis, is characterized by the breakdown of cartilage that causes the bones to rub together, resulting in pain, loss of movements and stiffness. Arthritis is usually a chronic condition.
For more information on Aleve and naproxen, visit the Aleve website at www.aleve.com. For more information on arthritis pain relief, visit www.arthritis.org
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.articledump.net/article/253282/articledump-Aleve-Vioxx-Celebrex-and-Bextra-What-You-Need-To-Know-About-Arthritis-Pain-Medications.html">Aleve, Vioxx, Celebrex, and Bextra: What You Need To Know About Arthritis Pain Medications</a>
BB link (for phorums):
[url=http://www.articledump.net/article/253282/articledump-Aleve-Vioxx-Celebrex-and-Bextra-What-You-Need-To-Know-About-Arthritis-Pain-Medications.html]Aleve, Vioxx, Celebrex, and Bextra: What You Need To Know About Arthritis Pain Medications[/url]
Related Articles:
How To Prevent Your 3rd Party Merchant Account From Suspension
Recognize and be Able to Differentiate and Explain the Following Access Control Models
Bookmark it:
|